The role of statin therapy in older adults: best practices and unmet challenges

John Stone1, Manish Kumar2, Ariela R Orkaby3

  • 1Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.

Insights

Statin use for primary cardiovascular disease (CVD) prevention in adults 75+ is debated due to limited trial data. Current evidence suggests potential benefits for those without severe comorbidities, pending further research.

Area of Science:

  • Geriatric Medicine
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) significantly impacts older adults' health and mortality.
  • Current guidelines for statin use in primary CVD prevention for individuals aged 75 and older are conflicting.
  • Older adults are often excluded from clinical trials, creating evidence gaps.

Purpose of the Study:

  • To review current national and international guidelines on statin use for primary CVD prevention in older adults.
  • To examine the evidence base informing these guidelines, considering age-related physiological changes.
  • To discuss clinical considerations for statin therapy in this demographic.

Main Methods:

  • A narrative review of literature using PubMed.
  • Focus on seven major national and international lipid-lowering therapy guidelines.
  • Analysis through two clinical case studies.

Main Results:

  • Conflicting recommendations exist for statin use in primary CVD prevention for older adults.
  • Evidence suggests statins may benefit older adults without significant comorbidities.
  • Ongoing randomized controlled trials aim to resolve current evidence gaps.

Conclusions:

  • The role of statins for primary CVD prevention in older adults requires further clarification.
  • Individualized treatment decisions are crucial, considering patient comorbidities.
  • Future research, including ongoing trials, will provide more definitive guidance.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
635
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
535
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517